Clinical trial
Mesenchymal Stromal Cell Therapy in Renal Recipients (MSCs)
This study will test the hypothesis that MSCs in combination with Everolimus facilitate Tacrolimus withdrawal, reduce fibrosis and decrease the incidence of opportunistic infections compared to standard tacrolimus dose.
Category | Value |
---|---|
Study start date | 2014-02-05 |